Malaria is a grave global health concern, impacting over 216 million individuals and resulting in approximately 445,000 fatalities in 2016. The African region bore the brunt of these deaths, accounting for almost 90% of the total, with children under 5 and pregnant women being the most severely affected demographics. In response to this crisis, three Brazilian universities have joined forces to develop new compounds with promising activity and safety profiles for malaria treatment. Initial candidates, identified as potential molecules for optimization studies of pharmacodynamic and pharmacokinetic properties, are currently under investigation. This proposal is centered on discovering new drug candidates within Brazil, a significant stride toward combating this devastating disease.